Ceftobiprole met primary and secondary efficacy endpoints Basilea plans to submit a New Drug Application (NDA) in the U.S. around year end 2022 Ad hoc.
We tend to blame the glut of disinformation in science on social media and the news, but the problem often starts with the scientific enterprise itself.
We tend to blame the glut of disinformation in science on social media and the news, but the problem often starts with the scientific enterprise itself.